REG - GlaxoSmithKline PLC - Director/PDMR Shareholding <Origin Href="QuoteRef">GSK.L</Origin>

GSKAnnouncement

13/10/2017 16:31

RNS Number : 6108T
GlaxoSmithKline PLC
13 October 2017
GlaxoSmithKline plc(the'Company')
Transaction notification
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms E Walmsley
b)
Position/status
Chief Executive Officer
c)
Initial notification/
amendment
Initial notification
2. 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name 
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Descriptionofthefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Natureofthetransaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017.
c)
Price(s)and 
volume(s)
Price(s)
Volume(s)
15.2659
408.631
d)
Aggregatedinformation
AggregatedvolumePrice
n/a (single transaction)
e)
Date ofthetransaction
2017-10-12
f)
Placeofthe transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr R G Connor
b)
Position/status
President, Global Manufacturing & Supply
c)
Initial notification/
amendment
Initial notification
2. 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name 
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Descriptionofthefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Natureofthetransaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017.
c)
Price(s)and 
volume(s)
Price(s)
Volume(s)
15.2659
71.145
d)
Aggregatedinformation
AggregatedvolumePrice
n/a (single transaction)
e)
Date ofthetransaction
2017-10-12
f)
Placeofthe transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr L Debruyne
b)
Position/status
President, Global Vaccines
c)
Initial notification/
amendment
Initial notification
2. 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name 
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Descriptionofthefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Natureofthetransaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017.
c)
Price(s)and 
volume(s)
Price(s)
Volume(s)
15.2659
735.251
d)
Aggregatedinformation
AggregatedvolumePrice
n/a (single transaction)
e)
Date ofthetransaction
2017-10-12
f)
Placeofthe transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr S Dingemans
b)
Position/status
Chief Financial Officer
c)
Initial notification/
amendment
Initial notification
2. 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name 
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Descriptionofthefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Natureofthetransaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017.
c)
Price(s)and 
volume(s)
Price(s)
Volume(s)
15.2659
793.924
d)
Aggregatedinformation
AggregatedvolumePrice
n/a (single transaction)
e)
Date ofthetransaction
2017-10-12
f)
Placeofthe transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr D S Redfern
b)
Position/status
Chief Strategy Officer
c)
Initial notification/
amendment
Initial notification
2. 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name 
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Descriptionofthefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Natureofthetransaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017.
c)
Price(s)and 
volume(s)
Price(s)
Volume(s)
15.2659
1,340.169
d)
Aggregatedinformation
AggregatedvolumePrice
n/a (single transaction)
e)
Date ofthetransaction
2017-10-12
f)
Placeofthe transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms C Thomas
b)
Position/status
SVP, HR
c)
Initial notification/
amendment
Initial notification
2. 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name 
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Descriptionofthefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Natureofthetransaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017.
c)
Price(s)and 
volume(s)
Price(s)
Volume(s)
15.2659
517.830
d)
Aggregatedinformation
AggregatedvolumePrice
n/a (single transaction)
e)
Date ofthetransaction
2017-10-12
f)
Placeofthe transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr P C Thomson
b)
Position/status
President, Global Affairs
c)
Initial notification/
amendment
Initial notification
2. 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name 
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Descriptionofthefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Natureofthetransaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017.
c)
Price(s)and 
volume(s)
Price(s)
Volume(s)
15.2659
628.735
d)
Aggregatedinformation
AggregatedvolumePrice
n/a (single transaction)
e)
Date ofthetransaction
2017-10-12
f)
Placeofthe transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Dr P J T Vallance
b)
Position/status
President, R&D
c)
Initial notification/
amendment
Initial notification
2. 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name 
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Descriptionofthefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Natureofthetransaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017.
c)
Price(s)and 
volume(s)
Price(s)
Volume(s)
15.2659
2,519.628
d)
Aggregatedinformation
AggregatedvolumePrice
n/a (single transaction)
e)
Date ofthetransaction
2017-10-12
f)
Placeofthe transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mrs K Thomson
b)
Position/status
PCA of Mr P C Thomson (President, Global Affairs)
c)
Initial notification/
amendment
Initial notification
2. 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name 
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Descriptionofthefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Natureofthetransaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017.
c)
Price(s)and 
volume(s)
Price(s)
Volume(s)
15.2659
118.755
d)
Aggregatedinformation
AggregatedvolumePrice
n/a (single transaction)
e)
Date ofthetransaction
2017-10-12
f)
Placeofthe transaction
London Stock Exchange (XLON)

This information is provided by RNS
The company news service from the London Stock Exchange
  END
DSHEXLFFDBFLFBZ